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Summary Using Cox's Proportional Hazard Model, we have demonstrated the influence of age, sex,
microscopic tumour type, extent of primary tumour, nodal status and the presence of metastases on
prognosis, in our population of 441 patients with thyroid carcinoma. The TNM classification contributes
significantly to survival, but does not include other contributory prognostic variables, whereas the prognostic
index developed by the EORTC thyroid study group, which takes account of age and histology, proved a
reliable predictor of survival for our patient group.
A number of factors are known to be of prognostic
importance in thyroid carcinoma. Among these are
age, sex, histological subtype and the extent of
disease at the time of diagnosis (Crile, 1953;
Halnan, 1966; Bell, 1975; Staunton & Skeet, 1979;
Byar et al., 1979). Thyroid cancer is a rare disease
(annual incidence rate of 1.5 per 100,000 of the
population in Scotland) and thus improvements in
assessment and refinement of prognostic models
cannot be based on randomised trials since these
are likely to be too small to have high statistical
power.
We present data here from 441 consecutive
patients with thyroid carcinoma referred for treat-
ment to a single population based referral centre.
Utilising univariate and multivariate statistical
methods, a number of factors have been examined
and their overall contribution to prognosis assessed.
The European Organisation for Research on Treat-
ment of Cancer (EORTC) thyroid study group
devised a prognostic index based on a Weibull
survival model (Byar et al., 1979) and we have
compared actual with predicted survival using their
scoring system in our patient group.
Patients and methods
A total of 495 patients with malignant neoplasm of
the thyroid were treated at the Department of
Radiotherapy, Western Infirmary, Glasgow between
1957 and 1982. This is a referral centre for most of
the West of Scotland. All the original case sheets
were reviewed and the relevant information was
transferred to a proforma and entered into a
computer file. Only patients with known duration
of follow up, known histopathological diagnosis
and with information on the necessary variables
were used. Death certification data is fraught with
inaccuracy in conditions with a relatively long
natural history and was not available for this study.
Therefore the contribution of deaths from inter-
current disease could not be assessed. The sample
was therefore restricted to 441 patients for whom
complete data sets were available. Patients were
treated by surgery (usually subtotal thyroidectomy),
external beam radiotherapy, radioactive iodine,
thyroid hormone supplementation and chemo-
therapy as clinically indicated. Screening for distant
metastases depended on the microscopic tumour
type. All patients had chest X-rays with thoracic
inlet views and skeletal X-rays if appropriate
symptomatology arose. Post-treatment follow-up
for well-differentiated tumours included regular
total body 1131 scans and latterly (last 5 years)
estimation of serum thyroylobulin levels. Regular
measurements of calcitonin concentrations were
utilised in post-therapeutic follow-up of those
patients treated for medullary thyroid cancer.
Despite the long duration of patient recruitment,
there was relative uniformity of treatment. The
median duration of follow-up was - 10 years.
Histological classification followed the principles of
Hedinger and Sobin (1974), codified for the World
Health Organisation, and all the microscopic
sections available were reviewed by a single
pathologist.
As there were relatively large numbers of cases
involved, it was possible to construct Kaplan-Meier
(1958) survival curves which were compared using
the log rank test (Peto & Peto, 1972). All factors
were subjected to univariate and multivariate
analysis and statistical differences were investigated
using the generalised Wilcoxon test. Patients were
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Table I EORTC prognostic score
Age at diagnosis (yr)
+ 10 ifmedullary
+45 if principle or associated cell
type is anaplastic
+ 10 ifT-category is T3
+ 15 in addition to above if there are
multiple distant metastatic sites
= Total score Risk group
<50 1
50-65 2
66-83 3
84-108 4
. 109 5
assigned a score using the EORTC thyroid study
group prognostic index and were assigned to one of
five 'risk groups' depending on total risk score
(Table I). Survival curves were constructed for the
five risk groups using the Kaplan-Meier technique
and identical statistical methods used to demon-
strate pairwise differences in survival. Multivariate
analysis was carried out using Cox's Proportional
Hazards Model (Cox, 1972) and it was possible to
investigate the independent effects of each variable
while making simultaneous adjustment for others
entered into the model. The assumption of propor-
tional hazards seemed, in all cases, reasonable as
judged by visual inspection of the hazard functions.
Results
The distribution of histological types and mean age
at presentation is summarised in Table II.
Microscopic tumour type has an important
influence on prognosis, as can be seen in Figure 1.
There is a distinct and highly statistically significant
gradation in survival with the following pairwise
comparisons; papillary better than follicular
(P<0.03); follicular better than lymphoma
(P<0.001); lymphoma better than anaplastic
(P<0.001).
The effect of age on survival is shown in
Figure 2. Patients were divided into two groups
dependent on age at presentation, either above or
below the arbitrary decade chosen. Univariate
analysis revealed that the difference in survival is
most marked when comparing those above and
below the age of 50 years (P<0.001). It is
important to note that the effects of death from
intercurrent diseases are not taken into account in
these calculations. Sex had no significant effect on
survival.
The disease was staged clinically and
pathologically according to the TNM classification
(Geneva, 1968) (Table III). The extent of the
primary tumour (Figure 3) has an effect on
prognosis (P<0.001) and there are significant
differences at P<0.01 for all pairwise comparisons,
implying that the more advanced the local disease,
the worse the prognosis. The curves in Figure 4
indicate that regional lymph node status has a
differential effect on survival. There is a significant
difference (P<0.01) when we compare No with all
other nodal groups, but there are only pairwise
differences between No or Ni and N2 or N3
(P<0.003).
There were not enough patients with metastases
in the well differentiated thyroid cancer group
(papillary) to draw meaningful statistical conclu-
sions with regard to survival. However, it was
apparent that the presence of metastases conferred
a worse prognosis (P<0.003) in follicular tumours.
The presence of metastases in patients with
anaplastic tumours did not significantly affect
survival.
Clinical presentation was coded according to a
variety of standard symptoms and signs. Virtually
Table II Distribution ofhistological types
Median interval
between onset
Number Median age at ofsymptoms
Histological presentation anddiagnosis
type Male Female (years) (months)
Papillary 38 (24%) 199 (76%) 45 12
Follicular 13 (20%) 53 (80%) 54 8
Anaplastic 24 (21%) 90 (79%) 63 2
Lymphoma 7 (11%) 57 (89%) 68 3
Medullary 6 18 57 6
Fibrosarcoma 1 4 61 3
Squamous 2 3 49 4
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Figure 2 Proportion ofpatients surviving according to age; _50 years (----); <50 years ( ).
all patients presented with painless swelling in the
neck, however the symptom cluster comprising
dysphonia, dysphagia and dyspnoea (Figure 5)
confers a worse prognosis (P<O.001) and is a likely
marker of locally advanced disease. These
symptoms are strongly correlated with signs
suggestive of local tissue invasion, such as fixity of
the thyroid to deep and superficial structures and
not surprisingly these signs are associated (Figure 6)
with a poorer survival (P<O.001).
The interval between the onset of symptoms and
presentation for treatment varied greatly (Table II).
Anaplastic tumours and lymphomas were
associated with a significantly shorter symptom
duration prior to presentation (P<0.005) than
papillary and follicular tumours.Table Ill Clinical and pathological staging by TNM
classification
Tstage Metastases N stage
1 2 3&4 + - 0 .1
Papillary 38 67 52 17 140 86 71
Follicular 8 25 33 6 60 48 18
Anaplastic 1 7 106 33 81 57 57
Lymphoma - 12 52 8 56 30 34
Medullary - 4 20 2 22 10 12
Other 2 5 9 1 15 7 9
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Figure 3 Proportion of patients surviving according to primary tumour stage; T1( ); T2 ( );
T3 (------).
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Figure 4 Proportion of patients surviving according to nodal status; No( ); N1 (- - -); N2 (. );
N3 (- - - --4-).
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Figure 5 Proportion of patients surviving according to symptoms at presentation (dysphonia, dysphagia and
dyspnoea); without symptoms ( ); with symptoms (------).
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Figure 6 Proportion of patients surviving according to signs at presentation (deep and superficial fixation of
the thyroid); without signs ( ); with signs (------).
Interpretation of univariate analysis, such as the
above, may be confounded by relationships which
exist within factors under study. Generally,
anaplastic tumours are more common in the
elderly, are associated with a brief symptom
interval prior to seeking medical advice, locally
advanced disease and are more likely to have
metastasised by the time of diagnosis. Clearly, it
would be impossible to separate and identify
important contributory prognostic factors in this
example because of the expected inter-relationship
between variables. We, therefore, carried out
multivariate analysis which allows computation of
the degree to which factors contribute indepen-
dently to the overall model. Using this approach,
we have tabulated significant explanatory variables
for individual histological subtypes (Table IV).
Using the EORTC prognostic index, all patients
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Figure 7 Proportion ofpatients surviving according to EORTC prognostic index (Table I).
Table IV Thyroid cancer - multivariate analysis
Variables contributing
to survival
Relative
Histological subtype P value risk
Anaplastic Signs 0.0757 1.17
Stage (T) 0.0279 1.42
Follicular Age 0.0218 1.72
Stage (T) 0.007 3.26
Stage (N) 0.0159 3.41
Papillary Age 0.0001
Symptoms 0.0587 2.29
Stage (T) 0.128 1.61
Stage (N) 0.033 1.95
Lymphoma Age 0.001 a
Symptoms 0.01 2.27
Stage (T) 0.002 2.52
aRelative risk was not computed as age was entered
as a continuous variable.
were given a risk score and were assigned to one of
five groups as previously described (Figure 7). The
number of patients in each group was: 1, 90; 2, 66;
3, 101; 4, 84; 5, 101. An overall comparison of
survival revealed there to be significant differences
between the risk groups (P<0.001); and in all
pairwise comparisons there were significant differ-
ences between all pairs at the P<0.001 level (except
between groups 3 and 4 which was at the
P<0.000014 level). The estimated 5 year survival
rates for each of the risk groups was as follows:
1, 97%; 2, 87%; 3, 56%; 4, 26%; 5, 3%.
Through cross tabulation of results it is possible
to determine the constituent subjects of each group.
Group 5 which carries the worst prognosis, consists
mainly of elderly patients with anaplastic tumours,
whereas group 1 contains the majority of young
patients with papillary or follicular tumours.
Discussion
The best information on prognostic factors is
undoubtedly obtained from randomised studies.
However, in dealing with conditions as rare as
thyroid cancer and where there have been few
recent developments in treatment innovation,
randomised clinical trials are hard to conduct
through lack of patients. Use of long, single centre
clinical services from a large referral centre can, in
these cirumstances, provide useful information.
In general, our results agree with previous studies
(Crile, 1953; Halnan, 1966; Bell, 1975; Staunton &
Skeet, 1979; Byar et al., 1979) that microscopic
tumour type, age at diagnosis, the extent of the
primary tumour, lymph node status and the
presence of metastases influence survival in patients
with thyroid carcinoma. In addition we have
demonstrated that specific symptom and sign
clusters suggestive of local tumour invasion are also
correlated with prognosis. The contribution of these
factors to survival for individual histological
subtypes was assessed by fitting Cox's Proportional
Hazard Model. This approach allows definition of
the importance of single variables while simul-
taneously adjusting for other variables in the
model.
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Distinction of the histological subtypes of thyroid
cancer has been codified by Hedinger & Sobin
(1974) and it is clear that microscopic tumour type
is probably the most important determinant of
survival. It is possible that more widespread use of
immunocytochemical techniques with definition of
specific tumour markers may help to describe
further immunohistological groups (dependent on
marker expression) with refinement of prognostic
models. Recent studies on small cell anaplastic
tumours from our laboratory would tend to
support this hypothesis (Burt et al., 1985).
Age at presentation is inversely related to
survival. The effect of age on survival is most
marked (P<0.0O1) comparing patients above and
below the age of 50 years, which is similar to the
age 'cut off' suggested by previous authors
(Halnan, 1966; Byar et al., 1979). The patients with
the well differentiated tumours have a relatively
long life span and it is impossible to determine the
relative contributions of death from intercurrent
disease and from thyroid carcinoma, as there was
no reliable death certification data. This could
obfuscate the inclusion of age as a prognostic
variable and should be borne in mind. At the other
end of the spectrum, however, there is little doubt
that virtually all deaths are attributable to
anaplastic thyroid carcinoma with little contribution
from intercurrent disease.
There is no general agreement on the influence of
sex on survival. Hirabayoshi & Lindsay (1961),
Halnan (1966) and Beaugie et al. (1976) all failed to
find an effect of sex on survival in keeping with our
results. Campbell & Soye (1975) and Cody (1976)
found males to have reduced survival, whereas Doll
(1969), in a collective review, found a significant
female advantage with papillary and follicular
tumours.
Not surprisingly, the extent of diease as
characterised by signs, symptoms and TNM
classification also contributes to prognosis.
Advanced local disease (T3), nodal involvement and
the presence of metastases all confer a worse
prognosis. It is interesting that the symptom cluster,
dysphonia, dyspnoea and dysphagia carried a worse
prognosis, irrespective of tumour type, and is a
presumptive marker of locally advanced disease.
The TNM classification was adopted by the
UICC (UICC, 1968) and modified on the basis of
recommendations of the EORTC. It has served as a
useful clinical and pathological marker of
prognosis. In this study we have demonstrated
several factors which contribute significantly to the
survival model which are not taken into account by
the TNM system (e.g. age, histology, symptoms). A
prognostic index which took account of these
variables would represent an advance in refining
any proposed prognostic models. Although there
are theoretical reasons (Hannequin, 1985) why a
prognostic index derived from study of a specific
patient group might not be generally applicable, we
used the scoring index derived by the EORTC
thyroid cancer group from their cooperative study
(this included data from 23 centres from various
European countries). The survival curves (Figure 7)
are all widely separated with highly significant
differences on pairwise comparison, and the
observed survival rates from our study and that of
the EORTC study group are in close agreement. In
view of the wide separation of the survival curves
for our patients in the different prognostic groups
we did not consider that subtle alterations in the
scoring system as a refinement based on our data,
e.g. symptom score, would improve differentiation
of the group survival curves or their closeness to
actual values.
In summary, we have shown the importance of
microscopic tumour type, age, signs and symptoms
at presentation, the extent of the primary tumour,
nodal status and metastases in determining survival
from thyroid carcinoma. In concord with the
EORTC thyroid cooperative study we have found
the simple TNM classification insufficiently accurate
as a guide to prognosis. We would recommend the
adoption of their prognostic index as an aid to
prediction of survival and as an adjuvant to
calculation of differential survival in randomised
clinical trials of treatment for thyroid cancer.
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